Podcast
The Uromigos
Hosted by The Uromigos · EN
Broadcasting the latest developments in GU cancer
Hosted by Brian Rini and Tom Powles
Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
492episodes
Episodes
Newest firstAll episodes
Episode 455: ESMO 2025 Urothelial Cancer Review
Oct 2300:27:19Tap to summarizeTom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.
Transcribe →Episode 454: ESMO 2025 Prostate and Kidney Cancer Review
Oct 2300:46:15Tap to summarizeSilke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025
Transcribe →Episode 453: ESMO 2025 - IMvigor011
Oct 2000:37:27Tap to summarizeAlex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA
Transcribe →Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer
Oct 1900:42:51Tap to summarizeMatt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
Transcribe →Episode 451: ESMO 2025 - PSMAddition
Oct 1900:30:31Tap to summarizeScott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC
Transcribe →Episode 450: ESMO 2025 - CAPITELLO
Oct 1900:21:35Tap to summarizeElena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025
Transcribe →Episode 449: ESMO 2025 - ENZARAD
Oct 1900:28:00Tap to summarizePaul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE
Transcribe →Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC
Oct 1800:46:21Tap to summarizeChristof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!
Transcribe →Episode 447: ESMO 2025 - RAMPART
Oct 1800:36:41Tap to summarizeJames Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
Transcribe →Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
Oct 1800:36:20Tap to summarizeCristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
Transcribe →